Overview of botulinum neurotoxins

Journal of Cosmetic and Laser Therapy

Volumn 9, Issue SUPPL. 1, 2007, Pages 11-16

  Lowe, Nicholas J ^a,b,c,d  

^a Cranley Clinic   (United Kingdom)

^b Clinical Research Specialists Inc   (United Kingdom)

^c UCLA School of Medicine ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Botulinum neurotoxin; Comparative studies; Dose selection; Duration

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; COSMETIC; NEURONOX; UNCLASSIFIED DRUG;

BLEPHAROSPASM; CLINICAL TRIAL; DRUG INDICATION; DYSTONIA; ESTHETICS; FACE; FACE MUSCLE; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; INJECTION SITE; NONHUMAN; PATIENT SAFETY; PATIENT SATISFACTION; PES EQUINOVARUS; PLASTIC SURGERY; PRIORITY JOURNAL; REJUVENATION; REVIEW; SINGLE DRUG DOSE; SPASTICITY; STRABISMUS; THERAPY EFFECT; TORTICOLLIS; TREATMENT PLANNING; WRINKLE;

BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; CLINICAL TRIALS AS TOPIC; COSMETIC TECHNIQUES; HUMANS; NEUROMUSCULAR AGENTS;

EID: 34548849152     PISSN: 14764172     EISSN: 14764180     Source Type: Journal    
DOI: 10.1080/17429590701635515     Document Type: Review

References (28)

1. Scott AB. Development of botulinum toxin therapy. Dermatol Clin. 2004;22:131-3.
2. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924-7.
3. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044-9.
4. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. Botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18:17-21.
5. Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. Plast Reconstr Surg. 1994;94:94-9.
6. Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol. 1996;35:569-72.
7. Carruthers JD, Lowe NJ, Menter MA, et al, for the BOTOX Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:1089-98.
8. Carruthers JA, Lowe NJ, Menter MA, et al, for the BOTOX Glabellar Lines I Study Group. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-9.
9. Lowe NJ, Ascher B, Heckmann M, et al, for the Botox Facial Aesthetics Study Team. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg. 2005;31:257-62.
10. Kane MA. The effect of botulinum toxin injections on the nasolabial fold. Plast Reconstr Surg. 2003;112 5 suppl: 66S-72S; discussion 73S-74S.
11. Flynn TC, Carruthers JA, Carruthers JA, Clark RE II. Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study. Dermatol Surg. 2003;29:943-50; discussion 950-1.
12. Lowe NJ, Yamauchi PS, Lask GP, et al. Botulinum toxin types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther. 2002;4:15-8.
13. Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004;51:223-33.
14. BOTOX COSMETIC [prescribing information]. Irvine (CA): Allergan, Inc.; 2005.
15. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol. 2006;55:975-80.
16. Lew H, Yun YS, Lee SY, Kim SJ. Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica. 2002;216:50-4.
17. Jost WH, Kohl A, Brinkmann S, Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm. 2005;112:905-13.
18. Roggenkämper P, Jost WH, Bihari K, et al, for the NT 201 Blepharospasm Study Team. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303-12.
19. Bhidayasiri R, Cardoso F, Truong DD. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol. 2006;13 suppl 1:21-9.
20. Tang X, Wan X. Comparison of BOTOX with a Chinese type A botulinum toxin. Chin Med J. 2000;113:794-8.
21. Rieder CR, Schestatsky P, Socal MP, et al. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol. 2007;30:39-42.
22. Flynn TC, Carruthers JA, Carruthers JA. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg. 2001;27:703-8.
23. Carruthers J, Fagien S, Matarasso SL, and the Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg. 2004;114 6 suppl:1S-22S.
24. Ahn MS, Catten M, Maas CS. Temporal brow lift using botulinum toxin A. Plast Reconstr Surg. 2000;105:1129-35.
25. Rzany B, Ascher B, Fratila A, et al. Efficacy and safety of 3-and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol. 2006;142:320-6.
26. Trindade de Almeida AR, Marques E, de Almeida J, et al. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007;33 special issue:S37-S43.
27. Heckmann M, Plewig G, for the Hyperhidrosis Study Group. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol. 2005;141:1255-9.
28. Sycha T, Kotzailias N, Kranz G, et al. UV-B irradiation attenuates dermal effects of botulinum toxin A: a randomized, double-blind, placebo-controlled study. Dermatol Surg. 2007;33 special issue:S92-S96.